Investigating how ALK4 affects pancreatic cancer biology and receptor trafficking
Role of ALK4 in Regulating Receptor Trafficking and Pancreatic Cancer Biology
This study is looking at how a protein called ALK4 affects pancreatic cancer, with the goal of finding new ways to help improve treatment for patients battling this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10866981 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of ALK4, a receptor involved in cell signaling, in the context of pancreatic cancer, which is known for its aggressive nature and low survival rates. The study aims to explore how the loss of ALK4 expression impacts cancer progression by enhancing the activity of other receptors and promoting cancer cell invasion and metastasis. By examining the molecular mechanisms at play, including the regulation of receptor trafficking and glycosylation, the research seeks to identify potential therapeutic targets that could improve treatment outcomes for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those with mutations or loss of ALK4 expression.
Not a fit: Patients with early-stage pancreatic cancer who do not have ALK4-related mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the effectiveness of treatments for pancreatic cancer.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer biology, suggesting that this approach could yield valuable insights and advancements.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Blobe, Gerard C — Duke University
- Study coordinator: Blobe, Gerard C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.